Journal of Pediatric Gastroenterology and Nutrition最新文献

{"title":"Subcutaneous infliximab in pediatric inflammatory bowel disease: Sustained remission, predictable pharmacokinetics, and real-world US implementation.","authors":"Patricia M Hughes, Nanci Pittman, Keith Benkov, Virginia Baez, Julia Festa, Juliana M Kennedy, Shouli Tung, Marla C Dubinsky, Elizabeth A Spencer","doi":"10.1002/jpn3.70510","DOIUrl":"10.1002/jpn3.70510","url":null,"abstract":"<p><strong>Objectives: </strong>Subcutaneous infliximab (IFX-SC) offers a convenient alternative to intravenous infliximab (IFX-IV) in inflammatory bowel disease (IBD) with more stable concentrations. Pediatric experience remains limited. We evaluated sustained clinical remission, pharmacokinetics, and safety/tolerability after transition from IFX-IV to IFX-SC in children with IBD.</p><p><strong>Methods: </strong>Prospective, single-US-center cohort of patients <18 in clinical remission on maintenance IFX-IV who transitioned to IFX-SC (2022-2025). Demographic, clinical, and pharmacokinetic data were collected. The primary outcome was sustained clinical remission (defined: Harvey-Bradshaw Index ≤ 4 or partial Mayo Score ≤ 2) ≥ 12 weeks (T1) after transition with no corticosteroids/hospitalization/surgery/therapy-cessation. Secondary outcomes were change in IFX concentrations, sustained remission at last follow-up, and safety/tolerability.</p><p><strong>Results: </strong>Of 36 prescribed, 22 (61%) initiated therapy (median age 15 [14-17] years; 73% Crohn's disease; 82% 120 mg q2 weeks); age-related insurance denial stopped 12/14 from starting. Sustained clinical remission at T1 and last follow-up (median 215 [162-273] days) was achieved in 20/22 (91%). Median IFX concentrations increased from 14.1 [9.7-22.4] µg/mL (IV trough) to 29.5 [23.1-35.0] µg/mL (SC steady-state)-a median 1.9 [1.5-2.9]-fold increase in paired samples. Two with prior anti-drug antibodies cleared them after switching. Adverse events were mild: injection-site pain (n = 4, one discontinued), transient pruritus (n = 1), device misfire (n = 1), worsening psoriasiform dermatitis (n = 1, discontinued); no serious adverse events or anaphylaxis occurred.</p><p><strong>Conclusions: </strong>Transition to IFX-SC maintained remission with an excellent safety profile. Steady-state IFX-SC levels approximated twice prior therapeutic IV troughs. Expanded labeling should be considered to ensure access reflects clinical necessity rather than administrative barriers.</p>","PeriodicalId":16694,"journal":{"name":"Journal of Pediatric Gastroenterology and Nutrition","volume":" ","pages":"703-709"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148562231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary management and feeding considerations of pediatric aerodigestive and upper gastrointestinal motility disorders.","authors":"Khalil El-Chammas, Kirsten B Jones, Joan Arvedson, Mary Boruta, Erick Toro-Monjaraz, Anita Sicolo, Anil Darbari, Rachel Rosen, Julie Khlevner","doi":"10.1002/jpn3.70509","DOIUrl":"10.1002/jpn3.70509","url":null,"abstract":"<p><strong>Objective: </strong>Pediatric aerodigestive and upper gastrointestinal (UGI) motility disorders are common and may be associated with compromised nutritional status and decreased quality of life. Traditional dietary recommendations for aerodigestive and UGI motility disorders have been rudimentary and largely based upon experience and common sense rather than scientific evidence.</p><p><strong>Methods: </strong>This position paper on the role of dietary therapy in pediatric aerodigestive and UGI motility disorders was developed by an expert group from the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Neurogastroenterology and Motility Committee that performed an evidence-based search of the literature on pediatric aerodigestive and UGI motility disorders. The literature was summarized and expert recommendations developed. The authorship met to discuss the evidence and statements. A consensus of at least 70% was required to approve a recommendation. Areas requiring further research were identified.</p><p><strong>Results: </strong>The literature on nutrition in pediatric aerodigestive and UGI motility disorders is limited. These patients benefit from interdisciplinary collaboration involving dietitians for ongoing assessment for growth and nutritional deficiencies as a result of their condition.</p><p><strong>Conclusion: </strong>This position paper provides the first set of expert recommendations on dietary considerations for pediatric patients with aerodigestive and UGI motility disorders. Further research is needed to bridge the gaps in knowledge as identified in this paper.</p>","PeriodicalId":16694,"journal":{"name":"Journal of Pediatric Gastroenterology and Nutrition","volume":" ","pages":"748-760"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646029/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148579230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneous outcomes in pediatric potential celiac disease: A multicenter longitudinal study.","authors":"Barak Laxer, Firas Rinawi, Nadya Ziv-Sokolovskaya, Raanan Shamir, Michal Kori, Anat Guz-Mark","doi":"10.1002/jpn3.70501","DOIUrl":"10.1002/jpn3.70501","url":null,"abstract":"<p><strong>Objectives: </strong>Potential celiac disease (PCD) is defined by positive celiac serology without villous atrophy. We aimed to study the outcome of children with PCD consuming a gluten-containing diet (GCD) over time.</p><p><strong>Methods: </strong>Children diagnosed with PCD between December 2018 and January 2022, in three pediatric gastroenterology centers, were longitudinally followed. Data were collected until October 2024, with a minimum follow-up of 12 months, unless celiac disease (CeD) was diagnosed earlier. Baseline data included demographics, celiac serology, and histological findings. Follow-up data included serology and biopsy results when performed.</p><p><strong>Results: </strong>The cohort included 88 patients with PCD, with a mean follow-up of 39 (range 12- 69) months. During this period, 17 (19.5%) patients progressed to CeD. Normalization of anti-tissue transglutaminase antibodies (tTG), while continuing a GCD, occurred in 33/88 (37.5%) while the rest remained with PCD. Specifically, among 16 patients with tTG levels >×10 upper limit of normal (ULN) at PCD diagnosis, three (18.8%) progressed to CeD, six (37.5%) normalized tTG while continued GCD, and the rest remained unchanged. Asymptomatic patients had higher rates of tTG normalization (61.9% vs. 35.8%, p = 0.0011). Neither tTG levels, nor having Marsh 1 histology, had a significant effect on PCD outcomes.</p><p><strong>Conclusions: </strong>Among pediatric patients with PCD, during a mean follow-up of 3.3 years, one-fifth progressed to CeD. Baseline serology levels do not reliably predict future mucosal deterioration. Over a third of children with PCD may achieve serological normalization while maintaining a GCD. This heterogeneous pattern of PCD warrants periodic serological and histological follow-up.</p>","PeriodicalId":16694,"journal":{"name":"Journal of Pediatric Gastroenterology and Nutrition","volume":" ","pages":"717-722"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does diagnosis by biopsy versus serology-only affect follow-up in celiac disease?","authors":"Maria Cristina Pacheco, Kai Kokesh, Jane Dickerson, Annemarie Rompca, Dale Lee","doi":"10.1002/jpn3.70506","DOIUrl":"10.1002/jpn3.70506","url":null,"abstract":"<p><strong>Objectives: </strong>Serology-only diagnosis of celiac disease is increasing, but few recent studies have looked at the outcomes of patients undergoing this approach. The aim of this study was to evaluate difference in clinical follow-up and decline in tissue transglutaminase immunoglobulin A (TTG IgA) for patients receiving serology-only versus biopsy diagnosis of celiac disease.</p><p><strong>Methods: </strong>Patients with a TTG IgA at or above 10 times upper limit of normal between October 1, 2020 and September 30, 2022 and were subsequently diagnosed with celiac disease with or without biopsy and had ongoing follow-up at Seattle Children's Hospital for 2 years after diagnosis were included. The patient's symptoms at diagnosis and follow-up visits, number of gastroenterology (GI) visits, timing of GI visits, number of dietician visits and timing of dietitian visits were documented. TTG IgA titers, human leukocyte antigen (HLA) antibody status, and esophagogastroduodenoscopy results were recorded. The data were analyzed using Student's t-test or the Wilcoxon rank-sum test as appropriate. Differences in categorical variables were assessed with chi-square.</p><p><strong>Results: </strong>Fifty-four patients were included. The mean age at diagnosis was 9.7 ± 4.3 years. Diagnosis was by biopsy in 32 (59%) patients and serology-only in 22 (41%) patients. The TTG IgA titers were similar at study baseline and decreased in both the biopsy and serology-only diagnostic groups. The p-value at all time points were not significant. The mean time to first dietitian visit, mean number of dietitian visits, and mean number of dietitian visits in the 24 months of follow-up was not significantly different between the groups.</p><p><strong>Conclusion: </strong>Serology-only diagnosis resulted in a similar rate of clinical follow-up and TTG IgA reduction when compared to biopsy diagnosis.</p>","PeriodicalId":16694,"journal":{"name":"Journal of Pediatric Gastroenterology and Nutrition","volume":" ","pages":"723-727"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148436802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mid-upper arm circumference, steatosis indices, and elastography for screening liver steatosis in children with overweight/obesity: A prospective cross-sectional study.","authors":"Selcuk Teke, Tugba Cavis, Yasin Maruf Ergen, Birce Izgi Akcay, Edibe Gozde Basaran, Necati Balamtekin","doi":"10.1002/jpn3.70554","DOIUrl":"10.1002/jpn3.70554","url":null,"abstract":"<p><strong>Objectives: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in children, and practical screening approaches are needed in populations with overweight/obesity. We aimed to evaluate mid-upper arm circumference (MUAC) as a simple marker for ultrasonography (US)-detected liver steatosis (LS) in children with overweight/obesity, to examine the performance of other non-invasive measures, and to assess MUAC-based composite cut-offs.</p><p><strong>Methods: </strong>In this study, 194 children with overweight/obesity aged 5-17 years were evaluated at a pediatric gastroenterology clinic. US-detected LS was defined as US grade ≥1. Liver stiffness was measured by two-dimensional shear-wave elastography (2D-SWE). Fasting biochemistry was obtained, and alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ratio, Hepatic Steatosis Index, and Framingham Steatosis Index were calculated. Associations between US-detected LS and anthropometric, biochemical, and liver stiffness measures were assessed using Spearman correlation, logistic regression, and receiver operating characteristic analyses; composite models used an odds ratio-rule approach.</p><p><strong>Results: </strong>US-detected LS was present in 55.2%. MUAC ≥ 30.0 cm yielded an area under the curve (AUC) of 0.738 for identifying US-detected LS. A composite rule of body mass index (BMI) z score ≥1.70 or MUAC ≥ 30.0 cm achieved 97.2% sensitivity and 54.0% specificity for identifying US-detected LS, with an AUC of 0.813, negative predictive value 94.0%, and positive predictive value 72.2%. Adding liver stiffness ≥5.68 kPa increased discrimination for identifying US-detected LS, with an AUC of 0.881.</p><p><strong>Conclusion: </strong>MUAC is a low-cost adjunct for screening US-detected LS in children with overweight/obesity. Simple composite cut-offs integrating MUAC with BMI showed high sensitivity in this cohort and may support initial risk stratification before ultrasonographic evaluation; adding liver stiffness yielded the highest discriminative performance.</p>","PeriodicalId":16694,"journal":{"name":"Journal of Pediatric Gastroenterology and Nutrition","volume":" ","pages":"616-623"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148865354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The ImproveCareNow Registry: Prediction of remission rates in paediatric Crohn's disease.","authors":"Jonathan Van Hecke, Gigi Veereman, Koen Huysentruyt, Bruno Hauser, Wilfried Cools, Niels F Cleymans, Jeremy Adler, Shehzad Saeed, Elisabeth De Greef","doi":"10.1002/jpn3.70519","DOIUrl":"10.1002/jpn3.70519","url":null,"abstract":"<p><strong>Objectives: </strong>Identifying predictors of poor outcomes (POPO) in paediatric Crohn's disease (CD) may guide therapy. We assessed predictors of 2-year non-remission (primary outcome) and time to first remission (TFR), corticosteroid-free remission (TCSFR, ≥3 months corticosteroid (CS) withdrawal and sustained remission (TSR, ≥6 months) (secondary outcomes) in paediatric CD.</p><p><strong>Methods: </strong>We retrospectively analysed prospectively collected data from 6959 paediatric CD patients (<18 years; 2007-2023) in the ImproveCareNow Registry. Remission was defined as a short Paediatric CD Activity Index <10. Logistic and Cox regression (α = 0.05), using R 4.5.0 with multiple imputation, identified predictors for both outcomes (at 0, 1, 5, 6, 12, and 24 months).</p><p><strong>Results: </strong>For the primary outcome, 53/794 patients (6.7%) failed to achieve remission during 2-year follow-up. Female sex (odds ratio [OR] = 3.12, 95% confidence interval [CI] 1.48-6.55) and need for ustekinumab after 1 year (OR = 14.70, 95% CI 4.37-49.46) predicted non-remission. For the secondary outcomes (n = 3290), mean TFR, TCSFR and TSR were 4.5, 16.4, and 8.2 months, respectively. Longer TFR was predicted by female sex (hazard ratio [HR] = 0.81, 95% CI 0.71-0.92) and the need for infliximab (IFX, HR = 1.15, 95% CI 1.00-1.32) at first visit. Longer TCSFR was associated with female sex (HR = 0.85, 95% CI 0.78-0.93), race (white HR = 0.83, 95% CI 0.74-0.93 and Asian HR = 1.42, 95% CI 1.05-1.92) and type of treatment at first visit (faster if IFX, slower if CS or immunomodulators). For TSR, predictors included age at diagnosis (HR = 1.06, 95% CI 1.02-1.11) and body mass index (BMI) (HR = 0.97, 95% CI 0.94-1.00).</p><p><strong>Conclusions: </strong>Clinical parameters (female sex, younger age, and higher BMI) and therapeutic strategy (early/late use of biologicals) are POPO and associated with longer time to remission in paediatric CD.</p>","PeriodicalId":16694,"journal":{"name":"Journal of Pediatric Gastroenterology and Nutrition","volume":" ","pages":"681-691"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148604223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and genetic features of pediatric hereditary polyposis syndromes in Israel: A nationwide multicenter cohort.","authors":"Shlomi Cohen, Tal Cozacov, Ilana Weintraub, Ron Shaoul, Oren Ledder, Dotan Yogev, Mordechai Slae, Ranya Egbarieh, Galina Ling, Anat Yerushalmy-Feler","doi":"10.1002/jpn3.70500","DOIUrl":"10.1002/jpn3.70500","url":null,"abstract":"<p><strong>Objectives: </strong>Hereditary polyposis syndromes in children are rare, heterogeneous disorders associated with significant morbidity and long-term risk of malignancy. Current data on their presentation, management, and outcomes in pediatric populations remain limited.</p><p><strong>Methods: </strong>We conducted a nationwide, multicenter, retrospective study that included children diagnosed with polyposis syndromes in eight pediatric gastroenterology centers in Israel. Demographic, genetic, clinical, endoscopic, and outcome data were collected.</p><p><strong>Results: </strong>A total of 105 children were included: 30 with juvenile polyposis syndrome (JPS), 26 with familial adenomatous polyposis (FAP), 19 with Peutz-Jeghers syndrome, 16 with phosphatase and tensin homolog-hamartoma tumor syndrome, 8 with constitutional mismatch repair deficiency syndrome, 5 with hereditary mixed polyposis syndrome, and 1 with Lynch syndrome. The median age at diagnosis was 8 years (interquartile range 4.1-11.5). Overall, 43 (41%) were of Ashkenazi Jewish origin, and a family history of polyposis was present in 54 (51%). Genetic testing was performed in 91 (87%), identifying pathogenic variants in 77 (73%) of them. Gastrointestinal symptoms were reported in 60 (57%) and extra-intestinal manifestations in 48 (46%). Polyposis-related surgery was required in 22 (21%) children. Malignancy in eight children included two cases of colorectal carcinoma and glioblastoma multiforme, T cell lymphoma with Wilm's tumor, medulloblastoma, ganglioneuroblastoma, and abdominal adenocarcinoma. Three mortality events were recorded.</p><p><strong>Conclusion: </strong>Israeli children with hereditary polyposis syndromes present with diverse clinical and genetic features. Despite increasing use of genetic testing, morbidity and malignancy risks remain substantial, highlighting the need for early recognition, surveillance, and multidisciplinary care.</p>","PeriodicalId":16694,"journal":{"name":"Journal of Pediatric Gastroenterology and Nutrition","volume":" ","pages":"637-643"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing language in pediatric disorders of gut-brain interaction: A practical guide to suggestive communication.","authors":"Arine M Vlieger, Julie Snyder, Sam Nurko, Marc A Benninga","doi":"10.1002/jpn3.70520","DOIUrl":"10.1002/jpn3.70520","url":null,"abstract":"","PeriodicalId":16694,"journal":{"name":"Journal of Pediatric Gastroenterology and Nutrition","volume":" ","pages":"583-586"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148592183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Upper and small bowel Crohn's disease in Brazilian children: Phenotypic characteristic and surgical risk\". Journal of Pediatric Gastroenterology and Nutrition. 2026;83(1):87-95.","authors":"","doi":"10.1002/jpn3.70526","DOIUrl":"10.1002/jpn3.70526","url":null,"abstract":"","PeriodicalId":16694,"journal":{"name":"Journal of Pediatric Gastroenterology and Nutrition","volume":" ","pages":"761"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148712823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early discharge after paediatric liver biopsy: A prospective observational study.","authors":"Fie Brantbjerg Tinning, Jakob Stensballe, Birthe Henriksen, Marianne Hørby Jørgensen, Bente Utoft Andreassen","doi":"10.1002/jpn3.70507","DOIUrl":"10.1002/jpn3.70507","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the safety of early discharge after percutaneous liver biopsy (PLB) in children using prospective bleeding risk stratification.</p><p><strong>Methods: </strong>In this prospective observational cohort study, paediatric patients scheduled for PLB were stratified into low- and high-risk groups based on bleeding history and laboratory values. Low-risk patients were discharged after 6 h, while high-risk patients were observed for 24 h. Outcomes included bleeding complications, transfusion requirements and readmissions.</p><p><strong>Results: </strong>A total of 167 patients underwent PLB; 119 (71%) were classified as low-risk and 48 (29%) as high-risk. Two minor bleeding events occurred, both in the high-risk group. Only high-risk patients received blood products prior to PLB.</p><p><strong>Conclusion: </strong>Pre-procedural risk stratification effectively identifies paediatric patients bleeding risk and eligibility for early discharge after PLB. This approach appears safe and can reduce hospital admission time for low-risk patients.</p>","PeriodicalId":16694,"journal":{"name":"Journal of Pediatric Gastroenterology and Nutrition","volume":" ","pages":"600-605"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148436853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}